StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the medical research company’s stock.
AXDX has been the subject of a number of other research reports. Craig Hallum reduced their price objective on Accelerate Diagnostics from $2.00 to $1.00 and set a hold rating for the company in a report on Monday, April 1st. William Blair restated an outperform rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd.
View Our Latest Research Report on AXDX
Accelerate Diagnostics Trading Up 5.7 %
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.16). The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $3.00 million. Analysts predict that Accelerate Diagnostics will post -2.37 EPS for the current fiscal year.
Institutional Investors Weigh In On Accelerate Diagnostics
A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. increased its holdings in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) by 3.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,219,724 shares of the medical research company’s stock after buying an additional 35,146 shares during the period. Griffin Asset Management Inc. owned 8.38% of Accelerate Diagnostics worth $4,781,000 as of its most recent filing with the Securities and Exchange Commission. 17.14% of the stock is currently owned by hedge funds and other institutional investors.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Stories
- Five stocks we like better than Accelerate Diagnostics
- What Are Dividend Challengers?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- 3 REITs to Buy and Hold for the Long Term
- Why Call Options Volume for These 2 Stocks Spiked Together
- Dividend Payout Ratio Calculator
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.